|
KMID : 1134120180210020182
|
|
Journal of Breast Cancer
2018 Volume.21 No. 2 p.182 ~ p.189
|
|
|
Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment
|
|
Jung Yong-Sik
Lee Soo-Jung
Lee June-Young
Noh Woo-Chul
Nam Seok-Jin
Park Byeong-Woo
Bae Young-Tae
Kang Sung-Soo
Park Heung-Kyu
Yoon Jung-Han
Kim Je-Ryong
Cho Se-Hun
Kim Lee-Su
Moon Byung-In
Jung Sung-Hoo
Lim Chol-Wan
Kim Sung-Yong
Park Ho-Yong
Song Jeong-Yoon
Lee Kwang-Man
Park Sung-Hwan
Jeong Joon
Park Hae-Lin
Kim Sung-Won
Kwak Beom-Seok
Kang Sun-Hee
Cho Young-Up
Gwak Geum-Hee
Park Yong-Lae
Kim Sang-Wook
Han Se-Hwan
|
|
|
Abstract
|
|
|
Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer.
Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined.
Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p<0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p=0.042). The mean BMD significantly decreased from ?0.39 at baseline to ?0.87 after 36 months (p<0.001).
Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.
|
|
|
KEYWORD
|
|
|
Breast neoplasms, Letrozole, Quality of life, Treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|